Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Roth initiates Acura Pharmaceuticals (ACUR +5.8%) at Buy with a $4.50 price target, representing a near 100% upside from Monday's closing price. On the earnings call earlier this month, Roth analyst Robert Cummins Hazlett had a good-natured back-and-forth with management regarding NEXAFED and OXECTA. [View news story]
    Think this company has tremendous upside with recent FDA findings. It just needs a little more help being recognized for what it is trying to accomplish and that is misuse and abuse of drugs that are addictive.
    May 14, 2013. 02:11 PM | Likes Like |Link to Comment
  • Acura Pharmaceuticals (ACUR) plummets 32% after news on Friday that Pfizer (PFE) has terminated the license to three development-stage drugs that use Acura’s technology.  [View news story]
    Once again the media is the blame for so called "mass hysteria". PFE is keeping oxceta, ACUR's drug and is selling and manufacturing as we speak. They merely cancelled three preliminary so called "pipeline" products. People should read before they react.
    Jul 30, 2012. 09:55 AM | Likes Like |Link to Comment
  • Short-Term Limits For 8 Small Cap Movers [View article]
    Anyone here anything on ACUR?
    Jan 23, 2012. 06:03 PM | Likes Like |Link to Comment